Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · IEX Real-Time Price · USD
0.405
-0.012 (-2.76%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States.
It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation.
The company was founded in 1984 and is based in San Diego, California.
Aethlon Medical, Inc.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 14 |
| CEO | James B. Frakes M.B.A. |
Contact Details
Address: 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 United States | |
| Phone | 858-459-7800 |
| Website | aethlonmedical.com |
Stock Details
| Ticker Symbol | AEMD |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000882291 |
| CUSIP Number | 00808Y307 |
| ISIN Number | US00808Y4061 |
| Employer ID | 13-3632859 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James B. Frakes M.B.A. | Interim Chief Executive Officer, Chief Financial Officer, Secretary and Director |
| Guy F. Cipriani BS (Eng.), MBA | Chief Operating Officer |
| Dr. Steven P. LaRosa M.D. | Chief Medical Officer |
| Dr. Lee D. Arnold Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 10-K | Annual Report |
| Jun 27, 2024 | 8-K | Current Report |
| May 24, 2024 | 8-K | Current Report |
| May 17, 2024 | 8-K | Current Report |
| May 16, 2024 | EFFECT | Notice of Effectiveness |
| May 16, 2024 | 424B4 | Prospectus |
| May 15, 2024 | EFFECT | Notice of Effectiveness |
| May 15, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 13, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |